These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35106617)

  • 21. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
    Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
    J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock.
    Le C; Chu F; Dunlay R; Villar J; Fedullo P; Wardi G
    Am J Emerg Med; 2018 Aug; 36(8):1380-1385. PubMed ID: 29321120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.
    Connor MJ; Salem C; Bauer SR; Hofmann CL; Groszek J; Butler R; Rehm SJ; Fissell WH
    Antimicrob Agents Chemother; 2011 Feb; 55(2):557-60. PubMed ID: 21115798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Piperacillin-Tazobactam Dosing in Septic Shock Patients Using Real-World Evidence: An Observational, Retrospective Cohort Study.
    Allen JM; Surajbali D; Q Nguyen D; Kuczek J; Tran M; Hachey B; Feild C; Shoulders BR; Smith SM; Voils SA
    Ann Pharmacother; 2023 Jun; 57(6):653-661. PubMed ID: 36154486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between emergency department sepsis order set design and delay to second dose piperacillin-tazobactam administration.
    Erickson RM; Sacha GL; Bauer SR; Fertel BS; Dettmer MR; Wesolek JL; Campbell MJ
    Am J Emerg Med; 2023 May; 67():41-47. PubMed ID: 36801535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
    Lheureux O; Trepo E; Hites M; Cotton F; Wolff F; Surin R; Creteur J; Vincent JL; Gustot T; Jacobs F; Taccone FS
    Liver Int; 2016 Jul; 36(7):1002-10. PubMed ID: 26645828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children.
    Hermans E; Devreese M; Zeitlinger M; Dhont E; Verougstraete N; Colman R; Vande Walle J; De Paepe P; De Cock PA
    Int J Antimicrob Agents; 2023 Nov; 62(5):106970. PubMed ID: 37716576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
    Donadello K; Antonucci E; Cristallini S; Roberts JA; Beumier M; Scolletta S; Jacobs F; Rondelet B; de Backer D; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2015 Mar; 45(3):278-82. PubMed ID: 25542059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
    Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Kollef MH
    Antimicrob Agents Chemother; 2010 May; 54(5):1742-8. PubMed ID: 20160050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
    De Waele JJ; Carrette S; Carlier M; Stove V; Boelens J; Claeys G; Leroux-Roels I; Hoste E; Depuydt P; Decruyenaere J; Verstraete AG
    Intensive Care Med; 2014 Mar; 40(3):380-7. PubMed ID: 24356862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
    Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
    J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.